Opinion|Videos|October 21, 2024
Unmet Needs and Future Perspective in the Frontline Management of mRCC
Author(s)Rana R. McKay, MD
Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel approaches that may address these challenges in the coming years.
Advertisement
Episodes in this series
- What unmet needs persist in first-line treatment of metastatic renal cell carcinoma (mRCC)? What advances do you anticipate in tyrosine kinase inhibitor–based therapies or other approaches for mRCC in the coming years?
Advertisement
Related to this article
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
4
Durability of PFS and OS Benefit vs. Historical Control
5